Home/Filings/4/0001209191-23-033802
4//SEC Filing

Harsch Mutya 4

Accession 0001209191-23-033802

CIK 0001566044other

Filed

Jun 1, 8:00 PM ET

Accepted

Jun 2, 4:34 PM ET

Size

5.4 KB

Accession

0001209191-23-033802

Insider Transaction Report

Form 4
Period: 2023-05-31
Harsch Mutya
CHIEF LEGAL OFFICER AND GC
Transactions
  • Award

    Common Stock

    2023-05-31$3.46/sh+3,664$12,66425,907 total
Footnotes (1)
  • [F1]These shares were acquired under the Issuer's Employee Share Purchase Plan ("ESPP") for the ESPP purchase period beginning on December 1, 2022 and ending on May 31, 2023 in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). In accordance with the terms of the ESPP, these shares were purchased at a price equal to 85% of the fair market value closing price of the Issuer's common stock on December 1, 2022.

Issuer

VYNE Therapeutics Inc.

CIK 0001566044

Entity typeother

Related Parties

1
  • filerCIK 0001727809

Filing Metadata

Form type
4
Filed
Jun 1, 8:00 PM ET
Accepted
Jun 2, 4:34 PM ET
Size
5.4 KB